Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve (FFR)



Status:Completed
Conditions:Peripheral Vascular Disease, Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - Any
Updated:5/12/2018
Start Date:March 2012
End Date:September 2014

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Efficacy of Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve Measurements

The purpose of this study is to demonstrate that intravenous regadenoson is equivalent to
intravenous Adenoscan® for the physiological assessment of intermediate coronary lesions.

This is a prospective open label, single center pilot trial that will evaluate regadenoson
compared to Adenoscan® to be given IV in the assessment of Fractional Flow Reserve. Forty
eight subjects will be enrolled and get Adenoscan® administered via IV followed by
Regadenoson IV.

Inclusion Criteria:

- Patients undergoing elective left heart catheterization

- Age ≥ 18 years (female not of child bearing potential)

- Able to provide written informed consent

Exclusion Criteria:

- Contraindications to administration of either Adenoscan® or Regadenoson

- High degree AV block, sick sinus syndrome without a functioning pacemaker

- Symptomatic bradycardia

- Recent STEMI (< 5 days)

- Recent NSTEMI (<5 days) if the peak CK is > 1000 IU

- Dipyridamole use within 24 hours

- Adenoscan® is contraindicated (hypersensitivity to Adenoscan®, Regadenoson, or
aminophylline

- Known severe bronchoconstrictive lung disease
We found this trial at
1
site
Ochsner Medical Center
1514 Jefferson Hwy.
New Orleans, Louisiana 70121
504-842-3000
Ochsner Medical Center Ochsner Medical Center is located near uptown New Orleans and includes acute...
?
mi
from
New Orleans, LA
Click here to add this to my saved trials